Table 2 HPV prevalences and number of types by HIV status, overall and among sexually experienced participants
HPV types | All participants N = 806 | Sexually experienced participants N = 637 | ||||
|---|---|---|---|---|---|---|
HIV-positive N = 306 n (%) | HIV-negative N = 500 n (%) | Chi-square p-value | HIV-positive N = 265 n (%) | HIV-negative N = 372 n (%) | Chi-square p-value | |
Any HPV | 253 (82.7) | 315 (63.0) | < 0.001 | 232 (87.6) | 280 (75.3) | < 0.001 |
Any HR-HPV | 223 (72.9) | 269 (53.8) | < 0.001 | 207 (78.1) | 244 (65.6) | < 0.001 |
Any LR-HPV | 187 (61.1) | 231 (46.2) | < 0.001 | 174 (65.7) | 209 (56.2) | 0.02 |
Quadrivalent vaccine | 105 (34.3) | 105 (21.0) | < 0.001 | 99 (37.4) | 99 (26.6) | 0.004 |
HR-HPV16/18 | 75 (24.5) | 71 (14.2) | < 0.001 | 69 (26.0) | 67 (18.0) | 0.01 |
LR-HPV6/11 | 47 (15.4) | 55 (11.0) | 0.07 | 47 (17.7) | 52 (14.0) | 0.20 |
Number of HPV types detected (among HPV+) | ||||||
1 | 51 (20.2) | 84 (26.7) | 0.02 | 42 (18.1) | 62 (22.1) | 0.04 |
2–4 | 111 (43.9) | 150 (47.6) | 102 (44.0) | 141 (50.4) | ||
≥ 5 | 91 (36.0) | 81 (25.7) | 88 (37.9) | 77 (27.5) | ||